Burzynski Research Institute, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsBurzynski Research Institute is a Delaware-incorporated clinical-stage company researching Antineoplastons, an unapproved cancer treatment, with no revenue and funding provided by its founder's medical practice.
What they do
The company was incorporated in 1984 to research, produce, and eventually sell compounds called Antineoplastons, which consist of growth-inhibiting peptides, amino acid derivatives, and organic acids. It currently provides Antineoplastons solely for use by Stanislaw R. Burzynski, M.D., Ph.D., in clinical research. The company has never generated significant operating revenue and has been funded by payments from Dr. Burzynski using funds from his medical practice. It reports these funds as additional paid-in capital.
Revenue drivers
- Antineoplastons (A10 and AS2-1) — The company's only potential product, not approved for sale anywhere; no revenue has ever been recorded from it.
- No commercial operations — The company has no commercial sales; all reported annual and quarterly revenue figures are $0.00.
- Dr. Burzynski's medical practice funding — Sole source of funding for operations, reported as additional paid-in capital, not revenue.
Recent performance
For the three months ended November 30, 2025, Burzynski Research Institute reported a net loss of $328,862, compared to a net loss of $352,239 for the same period a year earlier. Research and development expenses were $260,800 for the quarter, while general and administrative expenses were $68,062. For the nine months ended November 30, 2025, the net loss was $994,180, versus a $1,093,409 loss in the prior-year period. The company reported no revenue in any period. As of November 30, 2025, total assets were $2,265, total liabilities were $69,608, and stockholders' equity was negative $67,343.
Strategy
The company is reviewing data from Phase II clinical trials of Antineoplastons for various cancers. It sponsors a Phase III clinical trial using synthetic Antineoplastons A10 and AS2-1 injections, but that trial has not started enrollment. The company will not commence commercial operations unless the FDA approves Antineoplastons for sale and they are registered in the United States or Canada, of which there is no assurance. It may seek additional funding through the sale of securities. Future operations remain dependent on continued funding from Dr. Burzynski.
Risks
- No product approval — Antineoplastons have not been approved for sale or use by the FDA or anywhere in the world.
- No revenue and reliance on insider funding — The company has no significant operating revenue and its sole source of funding is payments from Dr. Burzynski's medical practice.
- Negative stockholders' equity and limited cash — As of November 30, 2025, stockholders' equity was negative $67,343 and cash was $2,165, while total liabilities were $69,608.
- Clinical trial uncertainty — The Phase III clinical trial for A10 and AS2-1 has not started enrollment, and there is no assurance of future trial progress or results.
Outlook
The company does not expect to generate significant operating revenue until Antineoplastons are approved for sale by the FDA. It will only commence commercial operations if Antineoplastons receive approval and are registered in the United States or Canada. The Phase III clinical trial has not started enrollment. The company may seek additional funding through the sale of securities, but its current operations depend on continued payments from Dr. Burzynski.